Table 1.
Baseline characteristics of breast cancer patients and healthy controls.
| Characteristics | Total Samples | GWAS Samples | Replication Samples |
|---|---|---|---|
| Cases | |||
| Sample size | 5,634 | 1,496 | 4,138 |
| Mean age at onset (SD) | 50.7 ± 11.1 | 49.3 ± 10.9 | 51.2 ± 11.2 |
| Mean age (SD) | 51.0 ± 11.1 | 50.0 ± 10.9 | 51.3 ± 11.1 |
| Familial history of cancer | |||
| Familial (%) | 265 (4.70%) | 24 (1.60%) | 241 (5.82%) |
| Sporadic (%) | 5,369 (95.30%) | 1472 (98.40%) | 3,897 (94.18%) |
| Menopausal status | 4,223 | 849 | 3,374 |
| Premenopausal (%) | 2,118 (50.15%) | 471 (55.48%) | 1,647 (48.81%) |
| Postmenopausal (%) | 2,105 (49.85%) | 378 (44.52%) | 1,727 (51.19%) |
| ER | 4,263 | 703 | 3,560 |
| Positive (%) | 2,773 (65.05%) | 456 (64.86%) | 2,317 (65.08%) |
| Negative (%) | 1,490 (34.95%) | 247 (35.14%) | 1,243 (34.92%) |
| PR | 4,262 | 702 | 3,560 |
| Positive (%) | 2,704 (63.44%) | 413 (58.83%) | 2,291 (64.35%) |
| Negative (%) | 1,558 (36.56%) | 289 (41.17%) | 1,269 (35.65%) |
| HER-2 | 4,254 | 698 | 3,556 |
| Positive (%) | 1,148 (26.99%) | 136 (19.48%) | 1,012 (28.46%) |
| Negative (%) | 3,106 (73.01%) | 562 (80.52%) | 2,544 (71.54%) |
| Molecular subtypes | 4,096 | 687 | 3,409 |
| Luminal A breast cancer | 1,088 (26.56%) | 207 (30.13%) | 881 (25.84%) |
| Lumina B breast cancer | 1,415 (34.55%) | 244 (35.52%) | 1,171 (34.35%) |
| HER-2 amplified breast cancer | 630 (15.38%) | 93 (13.54%) | 537 (15.75%) |
| Basal-like breast cancer | 963 (23.51%) | 143 (20.82%) | 820 (24.05%) |
| Controls | |||
| Sample size | 6,308 | 1,257 | 5,051 |
| Mean age (SD) | 47.4 ± 12.8 | 37.2 ± 11.9 | 50.3 ± 10.6 |